Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06276491
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-02-16
Brief Title:
Phase 1 Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Sponsor:
Xencor Inc
Organization:
Xencor Inc
Study Overview
Official Title:
A Phase 1 First-in-Human Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated and to determine an optimal and safe doses for further study The study will also evaluate effect of XmAb541 on tumor outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None